TY - JOUR T1 - Letrozole in the management of advanced ovarian cancer: an old drug as a new targeted therapy JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer DO - 10.1136/ijgc-2019-001128 SP - ijgc-2019-001128 AU - Claudia Marchetti AU - Francesca De Felice AU - Raffaella Ergasti AU - Giovanni Scambia AU - Anna Fagotti Y1 - 2020/03/27 UR - http://ijgc.bmj.com/content/early/2020/03/26/ijgc-2019-001128.abstract N2 - At present, there is no standard of care on the use of letrozole in ovarian cancer management. We performed a systematic review of the available literature addressing this issue. Data demonstrated a role for letrozole in ovarian cancer, in both the primary and recurrent setting. Letrozole, which has a favorable toxicity profile, seems to assure a prolonged recurrence-free interval, particularly when used as maintenance treatment, in low grade serous ovarian cancer; in recurrent cases it had also led to prolonged disease control. However, the optimal setting and biologically relevant patient population needs to be defined in larger trials. ER -